Probiotic triangle of success; strain production, clinical studies and product development

FEMS Microbiol Lett. 2020 Oct 21;367(19):fnaa167. doi: 10.1093/femsle/fnaa167.

Abstract

The successful development of probiotic foods and dietary supplements rests on three pillars; each with their specific challenges and opportunities. First, strain production; this depends on selecting the right strain with promising technological properties and safety profile. Further the manufacturing of the strain in a stable format at sufficiently high yield, following regulatory and customer requirements on culture media ingredients and other processing aids. The second pillar are the preclinical and clinical studies to document that the strain is a probiotic and exerts a health benefit on the host, the consumer. Especially when aiming for a regulator approved health claim, clinical studies need to be thoroughly performed; following appropriate ethical, scientific and regulatory guidelines. Finally, the probiotic will need to be incorporated in a product that can be brought to the consumer; a dietary supplement or a functional food. Because of the live nature of probiotics, specific challenges may need to be dealt with. Although experience from other strains is helpful in the process, the development is strain specific. Commercialisation and marketing of probiotics are strictly but differently regulated in most jurisdictions; defining what can and cannot be claimed.

Keywords: Bifidobacterium; Lactobacillus; health benefit; probiotics; product development; strain production.

MeSH terms

  • Clinical Studies as Topic
  • Dietary Supplements
  • Food Microbiology / trends*
  • Probiotics*